About
ATMPS Ltd have set about solving perhaps biggest problem for worldwide delivery of advanced therapies by implementing a real-time supply chain monitoring solution that reduces the significant administrative burden on hospitals and ensures complete safety. Advanced therapies still rely upon paper-based tracking in trials and proprietary systems for licensed therapies. Our patented Hataali platform solves these issues by being a blockchain based platform solution for all manufacturers, trials and therapies.
The blockchain delivers an immutable and permanent digital transactional record of chain of custody, identity and condition for precision medicine.
At ATMPS we passionately believe that new software platforms need to be affordable and interoperable (plug & play), allow multiple stakeholders to partner and collaborate easily, handle and deliver many different ATMPs, make the lives of healthcare staff easier and treat many more patients for any given resource.
Looking into the future, we have designed the platform to be future-proof and to provide the readiness for patient led care and product design, as well as the collection of RWE for ATMPs – the latter of which will become a crucial component of ongoing monitoring in the years ahead.
Key Facts
The approach we use is unique in the industry, as we take a holistic and open access view of the Advance Therapy ecosystem. We seek partnerships that allow us to make the end-to-end process modularly adaptable, transparent, and immutably connected, so we can iterate and improve rapidly. It also means we can bring down the total cost of ownership. The benefits of using our platform today are: • Fit for manufacturer purpose and not tainted by legacy pharma supply chain methodologies • It connects all stakeholders across sites regardless of their existing technical and interoperability maturity levels • Supports hospitals so that they can focus on the patient and not worry about managing and supporting complex proprietary advance therapy tracking solutions for each innovator • Can be used to support the entire development journey from discovery to commercialization – and from open lab to closed factory, with no critical data point ever missed • Data points are available for audit immediately with no possibility to reverse engineer any finding. Making the therapy’s digital data journey a valuable asset for the company’s future growth • Data can never be lost or destroyed • Digital automation means high value team members can work on high value tasks and not spend time on data handling and curating activities • Integration with MES and potentially empowering digitally controlled release by exception processes – critical for autologous therapies. There is a worldwide shortage of QPs (qualified persons) • Eliminate failures by learning instantaneously as each batch is processed leveraging the key data points captured • Regulators can digitally manage the full ecosystem by exception – no need to increase their resources, allow our digital automation and smart logic to do all the heavy lifting for regulatory compliance • The system is designed ready to support healthcare payers and providers that are looking to move to alternative payment methodologies • Hataali can interoperate with legacy systems, or operate as a standalone solution with a mobile first approach • Initial and final mile are dramatically improved. The platform supports scheduling services and precise and accurate monitoring of the therapies and its exact whereabouts. This means no unnecessary time wasted and patients can be kept informed in real-time.
Successes in UK/NHS
We have already partnered with Dresden University, the CGT Catapult/ATTCs and University Hospital Birmingham to demonstrate the ease with which we can integrate our Hataali Platform within an ATMP ecosystem and have demonstrated how it speeds up patient access to these life changing therapiesCompany details
Solutions
Improving quality & efficiency
Specialism
Operational Efficiency
Company details
Want to connect with this innovator?
Make an enquiryWebsite
www.atmps.net/Markets already exporting to
We have projects running in Germany and are actively engaged in other Eu markets and the US
Desired Markets
US, Eu ANZ, Japan and China are priorities
Desired customer types
Healthcare providers (hospitals), CDMOs, Pharma, Therapy manufactures, 3PLs, regulators